Axsome Therapeutics (NASDAQ:AXSM - Get Free Report)'s stock had its "buy" rating reiterated by stock analysts at HC Wainwright in a report issued on Thursday,Benzinga reports. They presently have a $180.00 price objective on the stock. HC Wainwright's price target would suggest a potential upside of 71.31% from the stock's current price.
Other research analysts have also issued reports about the company. Leerink Partners boosted their target price on Axsome Therapeutics from $110.00 to $150.00 and gave the stock an "outperform" rating in a report on Monday, February 10th. Royal Bank of Canada raised their price target on Axsome Therapeutics from $190.00 to $193.00 and gave the company an "outperform" rating in a report on Tuesday, April 29th. Wells Fargo & Company reiterated an "overweight" rating and issued a $165.00 price objective (up from $160.00) on shares of Axsome Therapeutics in a report on Tuesday, May 6th. Needham & Company LLC reissued a "buy" rating and issued a $153.00 price objective on shares of Axsome Therapeutics in a research report on Tuesday, April 1st. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Axsome Therapeutics in a report on Tuesday, February 11th. They set a "buy" rating and a $176.00 target price for the company. One research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Axsome Therapeutics has an average rating of "Buy" and a consensus target price of $172.14.
Read Our Latest Research Report on Axsome Therapeutics
Axsome Therapeutics Stock Performance
Axsome Therapeutics stock traded up $0.72 during midday trading on Thursday, reaching $105.07. 467,579 shares of the company's stock were exchanged, compared to its average volume of 689,220. The stock's 50-day simple moving average is $108.86 and its 200 day simple moving average is $105.79. The firm has a market cap of $5.17 billion, a price-to-earnings ratio of -17.54 and a beta of 0.46. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.04 and a current ratio of 2.11. Axsome Therapeutics has a 52 week low of $64.11 and a 52 week high of $139.13.
Insider Buying and Selling at Axsome Therapeutics
In other news, Director Mark Coleman sold 3,000 shares of Axsome Therapeutics stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $107.49, for a total value of $322,470.00. Following the completion of the sale, the director now directly owns 54,137 shares in the company, valued at approximately $5,819,186.13. The trade was a 5.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 22.30% of the company's stock.
Institutional Investors Weigh In On Axsome Therapeutics
Large investors have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd acquired a new position in Axsome Therapeutics in the 1st quarter valued at $25,000. Quantbot Technologies LP bought a new position in shares of Axsome Therapeutics in the first quarter worth $31,000. NBC Securities Inc. acquired a new position in Axsome Therapeutics in the first quarter valued at about $31,000. AlphaQuest LLC acquired a new position in Axsome Therapeutics in the first quarter valued at about $38,000. Finally, Neo Ivy Capital Management bought a new stake in Axsome Therapeutics during the first quarter worth about $41,000. Institutional investors and hedge funds own 81.49% of the company's stock.
About Axsome Therapeutics
(
Get Free Report)
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
Read More
Before you consider Axsome Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.
While Axsome Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
